Cancer biomarkers : section A of Disease markersHumansTriple Negative Breast NeoplasmsFemaleNeoadjuvant TherapyMiddle Aged
The predictive effect of the CD155-TIGIT immune checkpoint axis complex on neoadjuvant chemotherapy efficacy in triple-negative breast cancer: A preliminary study.
Keyu Yuan, Xin Ou, Shuzhen Lyu, Feng Shi, Quan Zhou, Yanjie Zhao, Jiangping Wu, Yu Cao, Yanping Li, Qingkun Song
Published: 202510.1177/18758592251390248
Abstract
BackgroundThe CD155-TIGIT axis, a breast cancer progression biomarker, underscored neoadjuvant chemotherapy (NAC) response variability in triple-negative breast cancer (TNBC), urging biomarker-based patient stratification for timely therapy.MethodsTh…
Preview only. Read the full abstract at the source